Beside producing monoclonal guinea pig antibody through phage display technology or hybridoma technology, Creative Biolabs offers an alternative choice to develop native guinea pig monoclonal antibody by our powerful Native™ Antibody Discovery Platform. This platform, which is combined with the antigen-specific B lymphocytes cytometry technology, is able to obtain target-specific guinea pig monoclonal antibodies paired with native heavy- and light-chains. In addition, this platform also enables the isolation of large amount of candidate antibodies that go through in vivo affinity maturation. Accordingly, the final produced native guinea pig monoclonal antibodies will possess extremely high specificity and affinity.